Tag: Cabozantinib,Erlotinib,Press Releases,Veristrat
-
VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study Results Presented at 16th World Conference On Lung Cancer
Biodesix, Inc. today announced new data regarding VeriStrat®, a serum proteomic test, and epidermal growth factor receptor mutation status in a Phase 1B/2 study of cabozantinib +/- erlotinib in advanced non-small cell lung cancer that is being presented at the World Conference on Lung Cancer.